Dentsply Sirona Stock Sinks On Missed Expectations, Lowered 2025 Guidance; CEO Unveils Return-To-Growth Plan
Nov 6, 2025, 2:41 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The decline in earnings and lowered guidance indicate potential long-term weakness, reminiscent of past declines during economic downturns. For example, in 2020, lower guidance similarly impacted stocks across sectors.
AI summary
What happened, with direct paths to the underlying reporting
XRAY reported adjusted earnings of 37 cents, below last year's 50 cents. Sales declined 5% year-over-year, totaling $904 million, slightly above expectations. CFO Matt Garth departed; interim CFO Leslie Varon has been appointed. Fiscal 2025 earnings guidance lowered to $1.60 per share, below consensus. Management's Return-to-Growth strategy aims for sustained growth over 24 months.
XRAY reported adjusted earnings of 37 cents, below last year's 50 cents.
CFO Matt Garth departed; interim CFO Leslie Varon has been appointed.
Fiscal 2025 earnings guidance lowered to $1.60 per share, below consensus.
Management's Return-to-Growth strategy aims for sustained growth over 24 months.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Needham downgraded XRAY and ZIMV to Hold due to poor growth. Dentsply Sirona missed Q4 earnings estimates significantly at 26 cents. Sales dropped 10.6% year over year, far below…